Peginterferon ?2a/Ribavirin FDA Antiviral Drugs Advisory Committee

11/15/02


Click here to start


Table of Contents

Peginterferon ?2a/Ribavirin FDA Antiviral Drugs Advisory Committee

Disclosure

What Information is Still Pending for the US Treating Community?

What Data Does the Treating Community Have Access to?

Impact of Patient Withdrawals: Absolute number of US patients

Clinical Questions: Absolute number of patients

Treatment Response by Geographic Location: Peginterferon alfa-2b/RBV*

Prevalence of HCV Infection, United States, 1988-1994

Prevalence (%) of Overweight/Obesity Among Males in US, 1999-2000*

If the numbers are available, how should they be analyzed?

Roche Statement on Clinical Trial Analysis

Conclusions (1)

Conclusions (2)

Author: Brian Murphy